Bio-Rad Reports First-Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Bio-Rad Labs (BIO) Tops Q1 EPS by 5c, Beats on Revenue; Offers Guidance
April 30, 2026 4:24 PM EDTBio-Rad Labs (NYSE: BIO) reported Q1 EPS of $1.89, $0.05 better than the analyst estimate of $1.84. Revenue for the quarter came in at $592.1 million versus the consensus estimate of $586.97 million.
Bio-Rad is updating its financial outlook for the full-year 2026. The Company currently expects non-GAAP,... More
